Northeast Investment Management Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Northeast Investment Management lessened its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 223,687 shares of the company’s stock after selling 2,228 shares during the period. Johnson & Johnson makes up 2.5% of Northeast Investment Management’s investment portfolio, making the stock its 12th largest position. Northeast Investment Management’s holdings in Johnson & Johnson were worth $36,542,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. DORCHESTER WEALTH MANAGEMENT Co boosted its holdings in Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its position in Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. raised its holdings in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after buying an additional 1,475 shares during the last quarter. Equitable Holdings Inc. lifted its stake in shares of Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after buying an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd grew its holdings in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after buying an additional 20,528 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Peter Fasolo sold 22,864 shares of the firm’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the sale, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the sale, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,707,775. The disclosure for this sale can be found here. Insiders have sold 300,750 shares of company stock valued at $52,311,677 over the last 90 days. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Down 0.3 %

NYSE:JNJ opened at $173.43 on Tuesday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The business has a fifty day moving average price of $176.33 and a 200-day moving average price of $171.44. The firm has a market capitalization of $453.43 billion, a price-to-earnings ratio of 24.15, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter in the prior year, the business posted $2.60 earnings per share. The business’s quarterly revenue was up 1.9% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is 62.95%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Raymond James lowered their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Morgan Stanley dropped their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Credit Suisse Group initiated coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Bank of America reduced their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Finally, Citigroup raised their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $182.42.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.